ResearcherNagoya UniversityNo recent work listed
Nao Takano
Matched on ORCID iD 0000-0001-8812-3758; OpenAlex author ID A5057442947. Sources: OpenAlex.
Their work
- Papers
- 3
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 18
2018: 1 paper · 2019: 1 paper · 2020: none · 2021: 1 paper
Papers 3
- The impact of early tumor shrinkage on conversion surgery and the survival in patients with unresectable locally advanced pancreatic cancer. Co-author DOI 10.1007/s00595-020-02220-2↗
- Phase II study of chemoradiotherapy combined with gemcitabine plus nab-paclitaxel for unresectable locally advanced pancreatic ductal adenocarcinoma (NUPAT 05 … Co-author DOI 10.18999/nagjms.81.2.233↗
- Phase I study of chemoradiotherapy using gemcitabine plus nab-paclitaxel for unresectable locally advanced pancreatic cancer. Co-author DOI 10.1007/s00280-018-3554-3↗
Closest collaborators
The 18 strongest of 18 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Masamichi Hayashi · 3 shared papers, 2018–2021 · strength 0.27
- Paper The impact of early tumor shrinkage on conversion surgery and the survival in patients with unresectable locally advanc… DOI 10.1007/s00595-020-02220-2↗
- Paper Phase II study of chemoradiotherapy combined with gemcitabine plus nab-paclitaxel for unresectable locally advanced pan… DOI 10.18999/nagjms.81.2.233↗
- Paper Phase I study of chemoradiotherapy using gemcitabine plus nab-paclitaxel for unresectable locally advanced pancreatic c… DOI 10.1007/s00280-018-3554-3↗
- Suguru Yamada · 3 shared papers, 2018–2021 · strength 0.27
- Paper The impact of early tumor shrinkage on conversion surgery and the survival in patients with unresectable locally advanc… DOI 10.1007/s00595-020-02220-2↗
- Paper Phase II study of chemoradiotherapy combined with gemcitabine plus nab-paclitaxel for unresectable locally advanced pan… DOI 10.18999/nagjms.81.2.233↗
- Paper Phase I study of chemoradiotherapy using gemcitabine plus nab-paclitaxel for unresectable locally advanced pancreatic c… DOI 10.1007/s00280-018-3554-3↗
- Yasuhiro Kodera · 3 shared papers, 2018–2021 · strength 0.27
- Paper The impact of early tumor shrinkage on conversion surgery and the survival in patients with unresectable locally advanc… DOI 10.1007/s00595-020-02220-2↗
- Paper Phase II study of chemoradiotherapy combined with gemcitabine plus nab-paclitaxel for unresectable locally advanced pan… DOI 10.18999/nagjms.81.2.233↗
- Paper Phase I study of chemoradiotherapy using gemcitabine plus nab-paclitaxel for unresectable locally advanced pancreatic c… DOI 10.1007/s00280-018-3554-3↗
- Tsutomu Fujii · 3 shared papers, 2018–2021 · strength 0.27
- Paper The impact of early tumor shrinkage on conversion surgery and the survival in patients with unresectable locally advanc… DOI 10.1007/s00595-020-02220-2↗
- Paper Phase II study of chemoradiotherapy combined with gemcitabine plus nab-paclitaxel for unresectable locally advanced pan… DOI 10.18999/nagjms.81.2.233↗
- Paper Phase I study of chemoradiotherapy using gemcitabine plus nab-paclitaxel for unresectable locally advanced pancreatic c… DOI 10.1007/s00280-018-3554-3↗
- Fuminori Sonohara · 2 shared papers, 2019–2021 · strength 0.20
- Paper The impact of early tumor shrinkage on conversion surgery and the survival in patients with unresectable locally advanc… DOI 10.1007/s00595-020-02220-2↗
- Paper Phase II study of chemoradiotherapy combined with gemcitabine plus nab-paclitaxel for unresectable locally advanced pan… DOI 10.18999/nagjms.81.2.233↗
- Yukio Ando · 2 shared papers, 2018–2019 · strength 0.13
- Paper Phase II study of chemoradiotherapy combined with gemcitabine plus nab-paclitaxel for unresectable locally advanced pan… DOI 10.18999/nagjms.81.2.233↗
- Paper Phase I study of chemoradiotherapy using gemcitabine plus nab-paclitaxel for unresectable locally advanced pancreatic c… DOI 10.1007/s00280-018-3554-3↗
- Masato Nagino · 2 shared papers, 2018–2019 · strength 0.13
- Paper Phase II study of chemoradiotherapy combined with gemcitabine plus nab-paclitaxel for unresectable locally advanced pan… DOI 10.18999/nagjms.81.2.233↗
- Paper Phase I study of chemoradiotherapy using gemcitabine plus nab-paclitaxel for unresectable locally advanced pancreatic c… DOI 10.1007/s00280-018-3554-3↗
- Hidemi Goto · 2 shared papers, 2018–2019 · strength 0.13
- Paper Phase II study of chemoradiotherapy combined with gemcitabine plus nab-paclitaxel for unresectable locally advanced pan… DOI 10.18999/nagjms.81.2.233↗
- Paper Phase I study of chemoradiotherapy using gemcitabine plus nab-paclitaxel for unresectable locally advanced pancreatic c… DOI 10.1007/s00280-018-3554-3↗
- Shinji Naganawa · 2 shared papers, 2018–2019 · strength 0.13
- Paper Phase II study of chemoradiotherapy combined with gemcitabine plus nab-paclitaxel for unresectable locally advanced pan… DOI 10.18999/nagjms.81.2.233↗
- Paper Phase I study of chemoradiotherapy using gemcitabine plus nab-paclitaxel for unresectable locally advanced pancreatic c… DOI 10.1007/s00280-018-3554-3↗
- Hiroki Kawashima · 2 shared papers, 2018–2019 · strength 0.13
- Paper Phase II study of chemoradiotherapy combined with gemcitabine plus nab-paclitaxel for unresectable locally advanced pan… DOI 10.18999/nagjms.81.2.233↗
- Paper Phase I study of chemoradiotherapy using gemcitabine plus nab-paclitaxel for unresectable locally advanced pancreatic c… DOI 10.1007/s00280-018-3554-3↗
- Junpei Yamaguchi · 2 shared papers, 2018–2019 · strength 0.13
- Paper Phase II study of chemoradiotherapy combined with gemcitabine plus nab-paclitaxel for unresectable locally advanced pan… DOI 10.18999/nagjms.81.2.233↗
- Paper Phase I study of chemoradiotherapy using gemcitabine plus nab-paclitaxel for unresectable locally advanced pancreatic c… DOI 10.1007/s00280-018-3554-3↗
- Yukihiro Yokoyama · 2 shared papers, 2018–2019 · strength 0.13
- Paper Phase II study of chemoradiotherapy combined with gemcitabine plus nab-paclitaxel for unresectable locally advanced pan… DOI 10.18999/nagjms.81.2.233↗
- Paper Phase I study of chemoradiotherapy using gemcitabine plus nab-paclitaxel for unresectable locally advanced pancreatic c… DOI 10.1007/s00280-018-3554-3↗
- Osamu Maeda · 2 shared papers, 2018–2019 · strength 0.13
- Paper Phase II study of chemoradiotherapy combined with gemcitabine plus nab-paclitaxel for unresectable locally advanced pan… DOI 10.18999/nagjms.81.2.233↗
- Paper Phase I study of chemoradiotherapy using gemcitabine plus nab-paclitaxel for unresectable locally advanced pancreatic c… DOI 10.1007/s00280-018-3554-3↗
- Yoshiki Hirooka · 2 shared papers, 2018–2019 · strength 0.13
- Paper Phase II study of chemoradiotherapy combined with gemcitabine plus nab-paclitaxel for unresectable locally advanced pan… DOI 10.18999/nagjms.81.2.233↗
- Paper Phase I study of chemoradiotherapy using gemcitabine plus nab-paclitaxel for unresectable locally advanced pancreatic c… DOI 10.1007/s00280-018-3554-3↗
- Masaya Suenaga · 1 shared paper, 2019 · strength 0.07
- Takuya Ishikawa · 1 shared paper, 2019 · strength 0.07
- Eizaburo Ohno · 1 shared paper, 2019 · strength 0.07
- Akihiro Hirakawa · 1 shared paper, 2019 · strength 0.07
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.